Xtant Medical Holdings, Inc. introduced its next‑generation synthetic bone graft, nanOss Strata, on December 11, 2025. The product is designed to more closely replicate the microarchitecture of natural bone and to enhance osteoconductivity, positioning the company to capture a larger share of the growing orthobiologics market.
NanOss Strata is made from hydroxycarbonapatite (HCA), a calcium‑phosphate ceramic that dissolves more readily than conventional hydroxyapatite. The higher solubility of HCA is expected to accelerate bone remodeling and improve integration with host tissue, according to the company’s technical data.
The graft is available in two sterile, preformed formats: compression‑resistant strips and prehydrated, moldable blocks. Both formats absorb blood quickly and can be shaped on the operating table, making them suitable for a range of orthopedic and spinal procedures, from spinal fusion to fracture fixation.
The launch follows a strong Q3 2025 earnings report in which Xtant reported revenue of $33.3 million, up 19% from the same quarter a year earlier, and a net income of $1.3 million after a $5.0 million loss in Q3 2024. Gross margin expanded to 66.1% from 58.4% year‑over‑year, driven by a favorable product mix and scale. The company’s financial performance has provided the resources and confidence to invest in new product development such as nanOss Strata.
CEO Sean Browne said the launch builds on the clinical success of the existing nanOss line and underscores Xtant’s commitment to advancing regenerative medicine. He added that the new graft will help surgeons achieve better patient outcomes and that the company remains focused on expanding its orthobiologics portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.